12/11
07:30 am
ifrx
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
Low
Report
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
12/4
07:18 am
ifrx
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
12/3
08:06 am
ifrx
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partners to a "market perform" rating.
Low
Report
InflaRx (NASDAQ:IFRX) was downgraded by analysts at Leerink Partners to a "market perform" rating.
12/3
08:05 am
ifrx
InflaRx (NASDAQ:IFRX) was given a new $2.00 price target on by analysts at Leerink Partners.
Medium
Report
InflaRx (NASDAQ:IFRX) was given a new $2.00 price target on by analysts at Leerink Partners.
11/11
07:03 am
ifrx
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
10/21
07:20 am
ifrx
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Medium
Report
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
10/14
12:15 pm
ifrx
InflaRx (NASDAQ:IFRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
InflaRx (NASDAQ:IFRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.